Second re-irradiation for DIPG progression, re-considering “old strategies” with new approaches
- 437 Downloads
Diffuse intrinsic pontine glioma (DIPG) is an aggressive infiltrative glioma for which no curative therapy is available. Radiation therapy (RT) is the only potentially effective intervention in delaying tumor progression, but only transiently. At progression, re-irradiation is gaining popularity as an effective palliative therapy. However, at second progression, exclusive symptomatic treatment is usually offered. Here we report two patients with DIPG at second progression who were treated with a second re-irradiation course with good response. Importantly, treatment was well tolerated with no irradiation associated acute toxicity identified.
KeywordsDIPG Second re-irradiation
Compliance with ethical standards
Conflicts of interest
The authors declare no conflicts of interest.
- 4.Massimino M, Biassoni V, Miceli R, Schiavello E 2014 Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neuroncol 305–12Google Scholar
- 5.Porkholm M, Valanne L, Lönnqvist T et al (2014) Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 61(9):1603–1609CrossRefPubMedGoogle Scholar
- 7.Puget BS, Blauwblomme T, Grill J (2012) Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? Am Soc Clin Oncol Educ Book 629–33Google Scholar
- 16.Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neuro-Oncol. 2011 ; 104(3):773–777.Google Scholar